Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials
Crossref DOI link: https://doi.org/10.1007/s00415-024-12273-9
Published Online: 2024-03-04
Published Print: 2024-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zid, Yasmin
Robertson, Neil P.
Text and Data Mining valid from 2024-03-04
Version of Record valid from 2024-03-04
Article History
Accepted: 22 February 2024
First Online: 4 March 2024